← All trials
NCT05807399
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 14, 2023
- Primary completion
- Feb 23, 2025
- Completion date
- Feb 23, 2025
- First posted
- Apr 11, 2023
- Last posted
- Dec 1, 2023
- Enrollment
- 360
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ludwig Maximilians UniversityLead sponsor
- Ludwig Maximilians UniversityStudy director
- Ludwig Maximilians UniversitySponsor investigator
- Radboud UniversityCollaborator
- University of LondonCollaborator
- University of California, San FranciscoCollaborator
- Ludwig Maximilians UniversityOfficial
- LegoChem Biosciences, IncCollaborator
- GlaxoSmithKlineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.